HIV/AIDS Topics IAS 2017: Trans Women Wary of Antiretroviral Drug and Hormone Interactions
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
Transgender women with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminizing hormones, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Gus Cairns
Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil fumarate (TDF), especially if combined with ritonavir, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: VRC01 Antibody Can Delay But Not Prevent HIV Rebound
- Details
- Category: Search for a Cure
- Published on Wednesday, 09 August 2017 00:00
- Written by Liz Highleyman
A broadly neutralizing antibody modestly delayed the resurgence of viral replication following interruption of antiviral therapy (ART) started during very early infection, but all study participants ultimately experienced viral rebound, according to results presented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
- Details
- Category: HIV Treatment
- Published on Wednesday, 09 August 2017 00:00
- Written by Liz Highleyman
A single oral dose of MK-8591, a long-acting antiretroviral in a novel drug class, suppressed HIV for 7 days in an early clinical trial, and the drug also appears to protect monkeys from rectal infection with an HIV-like virus, researchers reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: People with HIV Are at Risk for Liver Fibrosis and Steatosis
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Liz Highleyman
Metabolic syndrome, type 2 diabetes, and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do not have viral hepatitis coinfection, according to research presentedat the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: First Protease Inhibitor Combo Pill Maintains Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 09 August 2017 00:00
- Written by Liz Highleyman
The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill regimen, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
More Articles...
- IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease
- Coverage of the 2017 IAS Conference on HIV Science
- Coverage of the 2017 IAS Conference on HIV Science
- IAS 2017: Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
- IAS 2017: New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment
Web Design and Development by